A physicochemical modelling approach for estimating the stability of soluble receptor-bound tumour necrosis factor-alpha

Cytokine

Volumn 9, Issue 1, 1997, Pages 19-26

  Ramanathan, Murali ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antagonists; Antibodies; Cytokines; Modelling; Pharmacokinetics; Soluble receptors

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; EQUILIBRIUM CONSTANT; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MATHEMATICAL MODEL; PHARMACOKINETICS; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0030890636     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0131     Document Type: Article

References (23)

1. 1. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR (1993) Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717-2723.
2. 2. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR (1993) Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine anti-cytokine antibody complexes. J Immunol 151:1235-1244.
3. 3. Schobitz B, Pezeshki G, Pohl T, Hemmann U, Heinrich PC, Holsboer F, Reul JM (1995) Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 9:659-664.
4. 4. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329.
5. 5. Debets R, Savelkoul HF (1994) Cytokine antagonists and their potential therapeutic use. Immunol Today 15:455-458.
6. 6. Klein B, Brailly H (1995) Cytokine-binding proteins-stimulating antagonists. Immunol Today 16:216-220.
7. 7. Bendtzen K, Svenson M, Jonsson V, Hippe E (1990) Autoantibodies to cytokines - friends or foes? [see comments] [Review]. Immunol Today 11:167-169.
8. 8. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B (1992) High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22:2819-2824.
9. 9. Engelmann H, Novick D, Wallach D (1990) Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531-1536.
10. 10. Poiesi C, Albertini A, Ghielmi S, Cassani G, Corti A (1993) Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine 5:539-545.
11. 11. Petersen CM, Nykjaer A, Christiansen BS, Heickendorff L, Mogensen SC, Moller B (1989) Bioactive human recombinant tumor necrosis factor-alpha: an unstable dimer? Eur J Immunol 19:1887-1894.
12. 12. Narhi LO, Arakawa T (1987) Dissociation of recombinant tumor necrosis factor-alpha studied by gel permeation chromatography. Biochem Biophys Res Commun 147:740-746.
13. 13. Bemelmans MH, Gouma DJ, Buurman WA (1994) Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 6:608-615.
14. 14. Bemelmans MH, Gouma DJ, Buurman WA (1993) Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150:2007-2017.
15. 15. Jacobs CA, Beckmann MP, Mohler K, Maliszewski CR, Fanslow WC, Lynch DH (1993) Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Path 346:123-135.
16. 16. Bemelmans MH, Gouma DJ, Buurman WA (1993) LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol 151:5554-5562.
17. 17. Takahashi N, Brouckaert P, Bemelmans MH, Buurman WA, Fiers W (1994) Mechanism of induction of tolerance to tumour necrosis factor (TNF): no involvement of modulators of TNF bioavailability or receptor binding. Cytokine 6:235-242.
18. 18. Engelberts I, Moller A, Leeuwenberg JF, van der Linden CJ, Buurman WA (1992) Administration of tumor necrosis factor alpha (TNF alpha) inhibitors after exposure to TNF alpha prevents development of the maximal biological effect: an argument for clinical treatment with TNF alpha inhibitors. J Surg Res 53:510-4.
19. 19. Quezado Z, Banks SM, Natanson C (1995) New strategies for combatting sepsis - the magic bullets missed the mark . . . but the search continues. Trends Biotechnol 13:56-63.
20. 20. Stone R (1994) Search for sepsis drugs goes on despite past failures [news]. Science 264:365-367.
21. 21. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771-783.
22. 22. Callard RE, Gearing AJH (1994) The Cytokine Factsbook. New York, Academic Press.
23. 23. D'Argenio DZ, Schlumitzky A (1992) Users Guide: Adapt II Mathematical software for pharmacokinetic/pharmacodynamic systems analysis. Biomedical Simulations Resource. University of Southern California, Los Angeles, CA.